MAP3K7 and metabolic dysfunction-associated steatohepatitis: Recent reports have further determined that TAK1 is involved in autophagy, fatty acid oxidation, steatosis, and carcinogenesis, suggesting that TAK1 is a putative therapeutic target for nonalcoholic steatohepatitis and cancer (Inokuchi et al., 2010; Yang et al., 2013; Inokuchi-Shimizu et al., 2014; Mukhopadhyay and Lee, 2020).